Journal
MEDICAL CLINICS OF NORTH AMERICA
Volume 97, Issue 3, Pages 369-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mcna.2012.12.012
Keywords
Alzheimer disease; Cerebrospinal fluid; Biomarkers; Early diagnosis; Amyloid of A beta; Tau protein
Categories
Ask authors/readers for more resources
This article gives an updated account of the clinical application of cerebrospinal fluid (CSF) biomarkers for Alzheimer disease (AD). The clinically most relevant biomarkers, total tau, phospho-tau and A beta 42 are discussed, and how they may be used, together with other diagnostic investigations, to make a predementia diagnosis of AD. Recent findings in sporadic and genetic preclinical AD are also discussed and, more specifically, what the biomarkers have taught us on the sequence of events in the pathogenic process underlying AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available